Similarly, clinical data from the MSK-IMPACT Heme project [27] showed worse survival for FAT1-mutated blood cancer patients and FAT1-mutated ALCL subgroup compared to non-mutated cases (Fig. 1i), suggesting a general prognostic role of FAT genes in hematological cancer. This evidence concerns the gene FAT1 and anaplastic large cell lymphoma.